White adipose tissue apolipoprotein C-I secretion in relation to delayed plasma clearance of dietary fat in humans

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2785-2793

  Wassef, Hanny ^a,b,c   Salem, Huda ^a   Bissonnette, Simon ^a,c   Baass, Alexis ^a,b   Dufour, Robert ^a,c   Davignon, Jean ^a,b,c   Faraj, May ^a,d  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Montreal Diabetes Research Center MDRC   (Canada)

Author keywords

Lipoprotein metabolism; Postprandial triglyceride clearance; Stable isotopes; Subcutaneous white adipose tissue; Transferable apolipoproteins

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN E; CARBON 13; FATTY ACID; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; APOLIPOPROTEIN C I, HUMAN; APOLIPOPROTEIN C-I, HUMAN; TRIOLEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FAT INTAKE; FEMALE; HUMAN; INSULIN SENSITIVITY; LIPID DIET; OBESITY; PLASMA CLEARANCE; POSTMENOPAUSE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN SECRETION; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE; AREA UNDER THE CURVE; BIOPSY; BLOOD; CANADA; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SECRETION (PROCESS); TIME;

ADIPOSE TISSUE, WHITE; AGED; APOLIPOPROTEIN C-I; AREA UNDER CURVE; BIOPSY; DIETARY FATS; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; LIPOPROTEINS, HDL; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; QUEBEC; TIME FACTORS; TRIGLYCERIDES; TRIOLEIN;

EID: 84871882059     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300306     Document Type: Article

References (46)

1. Sniderman AD, Cianfone K, Arner P, Summers LK, Frayn KN. The adi-pocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol. 1998;18:147-151.
2. Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res. 2005;96:1042-1052.
3. Frayn KN. Adipose tissue as a buffer for daily lipid fux. Diabetologia. 2002;45:1201-1210.
4. Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol. 2007;18:633-637.
5. Faraj M, Sniderman AD, Cianfone K. ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J Lipid Res. 2004;45:657-666.
6. Frayn KN, Arner P, Yki-Järvinen H. Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem. 2006;42:89-103.
7. Faraj M, Lu HL, Cianfone K. Diabetes, lipids, and adipocyte secreta-gogues. Biochem Cell Biol. 2004;82:170-190.
8. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25:1277-1294.
9. Westerterp M, Van Eck M, de Haan W, Offerman EH, Van Berkel TJ, Havekes LM, Rensen PC. Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol effux from macrophages. Atherosclerosis. 2007;195:e9-16.
10. Lauer SJ, Walker D, Elshourbagy NA, Reardon CA, Levy-Wilson B, Taylor JM. Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J Biol Chem. 1988;263:7277-7286.
11. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest. 1973;52:32-38.
12. Annuzzi G, Holmquist L, Carlson LA. Concentrations of apolipopro-teins B, C-I, C-II, C-III, E and lipids in serum and serum lipoproteins of normal subjects during alimentary lipaemia. Scand J Clin Lab Invest. 1989;49:73-81.
13. Björkegren J. Dual roles of apolipoprotein CI in the formation of athero-genic remnants. Curr Atheroscler Rep. 2006;8:1-2.
14. Gautier T, Masson D, de Barros JP, Athias A, Gambert P, Aunis D, Metz-Boutigue MH, Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem. 2000;275:37504-37509.
15. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001;12:297-304.
16. de Haan W, Out R, Berbée JF, van der Hoogt CC, van Dijk KW, van Berkel TJ, Romijn JA, Jukema JW, Havekes LM, Rensen PC. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. Biochem Biophys Res Commun. 2008;377:1294-1298.
17. Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceride-mia due to inhibition of hepatic lipase. J Lipid Res. 2002;43:2136-2145.
18. Westerterp M, de Haan W, Berbée JF, Havekes LM, Rensen PC. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res. 2006;47:1203-1211.
19. Westerterp M, Berbée JF, Delsing DJ, Jong MC, Gijbels MJ, Dahlmans VE, Offerman EH, Romijn JA, Havekes LM, Rensen PC. Apolipoprotein C-I binds free fatty acids and reduces their intracellular esterifcation. J Lipid Res. 2007;48:1353-1361.
20. Jong MC, van Dijk KW, Dahlmans VE, Van der Boom H, Kobayashi K, Oka K, Siest G, Chan L, Hofker MH, Havekes LM. Reversal of hyper-lipidaemia in apolipoprotein C1 transgenic mice by adenovirus-medi-ated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem J. 1999;338 (Pt 2): 281-287.
21. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglycer-ide-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266:18259-18267.
22. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:22453-22459.
23. Berbée JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res. 2005;46:297-306.
24. Jong MC, Voshol PJ, Muurling M, Dahlmans VE, Romijn JA, Pijl H, Havekes LM. Protection from obesity and insulin resistance in mice over-expressing human apolipoprotein C1. Diabetes. 2001;50:2779-2785.
25. Hamsten A, Silveira A, Boquist S, Tang R, Bond MG, de Faire U, Björkegren J. The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. J Am Coll Cardiol. 2005;45:1013-1017.
26. Björkegren J, Silveira A, Boquist S, Tang R, Karpe F, Bond MG, de Faire U, Hamsten A. Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:1470-1474.
27. Björkegren J, Boquist S, Samnegârd A, Lundman P, Tornvall P, Ericsson CG, Hamsten A. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceride-mia in normolipidemic patients with coronary artery disease. Circulation. 2000;101:227-230.
28. Wassef H, Bernier L, Davignon J, Cohn JS. Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells. J Nutr. 2004;134:2935-2941.
29. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipid-emia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25:567-579.
30. Reyes-Soffer G, Holleran S, Karmally W, Ngai CI, Chen NT, Torres M, Ramakrishnan R, Blaner WS, Berglund L, Ginsberg HN, Tuck C. Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. J Lipid Res. 2009;50:1901-1909.
31. Bastard JP, Vandernotte JM, Faraj M, Karelis AD, Messier L, Malita FM, Garrel D, Prud'homme D, Rabasa-Lhoret R. Relationship between the hyperinsulinemic-euglycaemic clamp and a new simple index assessing insulin sensitivity in overweight and obese postmenopausal women. Diabetes Metab. 2007;33:261-268.
32. Vandermeersch A, Ameye S, Puype D, Petitjean D, De Buyzere M, Langlois MR. Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment. Clin Chim Acta. 2010;411:1361-1366.
33. Kim KW, McCormick J, Helmering J, Véniant MM, Wang M. An optimized fast-performance liquid chromatography method for analyzing lipoprotein profles using microliter volumes of serum. Anal Biochem. 2008;376:268-274.
34. Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J Jr, Davignon J. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1996;16:149-159.
35. Cohn JS, Tremblay M, Batal R, Jacques H, Veilleux L, Rodriguez C, Bernier L, Mamer O, Davignon J. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2002;43:1680-1687.
36. Moldes M, Beauregard G, Faraj M, Peretti N, Ducluzeau PH, Laville M, Rabasa-Lhoret R, Vidal H, Clément K. Adiponutrin gene is regulated by insulin and glucose in human adipose tissue. Eur J Endocrinol. 2006;155:461-468.
37. Faraj M, Beauregard G, Loizon E, Moldes M, Clément K, Tahiri Y, Cianfone K, Vidal H, Rabasa-Lhoret R. Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin. J Endocrinol. 2006;191:427-435.
38. Faraj M, Jones P, Sniderman AD, Cianfone K. Enhanced dietary fat clearance in postobese women. J Lipid Res. 2001;42:571-580.
39. Innis-Whitehouse W, Li X, Brown WV, Le NA. An effcient chromato-graphic system for lipoprotein fractionation using whole plasma. J Lipid Res. 1998;39:679-690.
40. Zannis VI, Kan H Y, Kritis A, Zanni E, Kardassis D. Transcriptional regulation of the human apolipoprotein genes. Front Biosci. 2001;6:D456-D504.
41. Shih SJ, Allan C, Grehan S, Tse E, Moran C, Taylor JM. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem. 2000;275:31567-31572.
42. Li RX, Ding YB, Zhao SL, Xiao YY, Li QR, Xia FY, Sun L, Lin X, Wu JR, Liao K, Zeng R. Secretome-derived isotope tags (SDIT) reveal adipocyte-derived apolipoprotein C-I as a predictive marker for cardiovascular disease. J Proteome Res. 2012;11:2851-2862.
43. Takahashi Y, Inoue J, Kagechika H, Sato R. ApoC-III gene expression is sharply increased during adipogenesis and is augmented by retinoid X receptor (RXR) agonists. FEBS Lett. 2009;583:493-497.
44. James PF, Dogovski C, Dobson RC, Bailey MF, Goldie KN, Karas JA, Scanlon DB, O'Hair RA, Perugini MA. Aromatic residues in the C-terminal helix of human apoC-I mediate phospholipid interactions and particle morphology. J Lipid Res. 2009;50:1384-1394.
45. Rahim A, Naf-valencia E, Siddiqi S, Basha R, Runyon CC, Siddiqi SA. Proteomic analysis of the very low density lipoprotein (VLDL) transport vesicles. J Proteomics. 2012;75:2225-2235.
46. Malmendier CL, Lontie JF, Grutman GA, Delcroix C. Metabolism of apolipoprotein C-I in normolipoproteinemic human subjects. Atherosclerosis. 1986;62:167-172.